Dr. Martin Wax is a clinician-scientist and currently the CEO and Board Chairman, Mimetogen Pharmaceuticals, Inc. located in Montreal, Canada, and Co-Founder, PanOptica, Inc.
He was the Chief Medical Officer and Executive Vice-President of R&D, at PanOptica, Inc., a private US biotechnology company specializing in ophthalmic pharmaceuticals from 2009-2020. Prior to that he was Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories from 2003-2008. Dr. Wax has authored more than 200 scientific and clinical publications focusing on glaucoma pharmacology and mechanisms of neuronal cell death in glaucoma.
